NovaDel Pharma Inc, announced that it received a Notice of Allowance from the United States Patent and Trademark Office (US PTO) for claims under US Patent Application No. 10/671,715, entitled 'Buccal, Polar and Non-polar Spray Containing Zolpidem', which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist Oral Spray spray technology. Once issued, this patent will expire in 2018.

As previously announced, NovaDel's Zolpimist (zolpidem tartrate) 5 mg and 10 mg Oral Spray product is approved by the US Food and Drug Administration (FDA) for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpimist is NovaDel's second product approved by the FDA that uses NovaDel's proprietary NovaMist oral spray technology. Zolpimist contains zolpidem tartrate, the same active ingredient as Ambien, the world's leading sedative hypnotic for the treatment of insomnia.

NovaDel maintains an extensive worldwide portfolio of intellectual property rights for select compounds using its pioneering oral spray delivery system.

NovaDel Pharma is a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed drugs.